These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165 [TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059 [TBL] [Abstract][Full Text] [Related]
10. Single dose oral rofecoxib for postoperative pain. Barden J; Edwards J; Moore RA; McQuay HJ Cochrane Database Syst Rev; 2005 Jan; (1):CD004604. PubMed ID: 15674955 [TBL] [Abstract][Full Text] [Related]
11. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J; Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337 [TBL] [Abstract][Full Text] [Related]
12. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687 [TBL] [Abstract][Full Text] [Related]
13. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915 [TBL] [Abstract][Full Text] [Related]
15. Single dose oral rofecoxib for acute postoperative pain in adults. Bulley S; Derry S; Moore RA; McQuay HJ Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004604. PubMed ID: 19821329 [TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP; Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224 [TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
18. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ; N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881 [TBL] [Abstract][Full Text] [Related]
19. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Matheson AJ; Figgitt DP Drugs; 2001; 61(6):833-65. PubMed ID: 11398914 [TBL] [Abstract][Full Text] [Related]
20. Celecoxib for rheumatoid arthritis. Fidahic M; Jelicic Kadic A; Radic M; Puljak L Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012095. PubMed ID: 28597983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]